Hepatitis C News and Research

Latest Hepatitis C News and Research

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Mortality from all causes higher among hepatitis C-infected patients, study finds

Mortality from all causes higher among hepatitis C-infected patients, study finds

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech announces the pricing for ROTAVAC vaccine

GAVI welcomes lower pentavalent vaccine price

GAVI welcomes lower pentavalent vaccine price

Primary care providers treat hepatitis C patients effectively through Project ECHO model

Primary care providers treat hepatitis C patients effectively through Project ECHO model

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

Technology, expert training and real-time feedback improves Hepatitis C outcomes

Technology, expert training and real-time feedback improves Hepatitis C outcomes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.